Researchmoz : Global Radiopharmaceuticals/Nuclear Medicine Market Analysis - Trends & Forecast to 2020

Share Article

ResearchMoz.us include new market research report" Global Radiopharmaceuticals/Nuclear Medicine Market Analysis - Trends & Forecast to 2020" to its huge collection of research reports.Browse reports in Pharmaceutical Market @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

ResearchMoz

ResearchMOZ

Global Radiopharmaceuticals/Nuclear Medicine Market Analysis - Trends & Forecast to 2020

North America holds the largest share for nuclear medicine market, followed by Europe. The U.S. market is highly supported by the Mo-99 production of NRU reactor (Canada) and ongoing researches in different clinical institutes such as National Cancer Institute, Avid Radiopharmaceuticals and so on. Besides developed markets, the Asia-Pacific region is expected to show a remarkable growth in the coming years. Asia-Pacific (APAC) and Rest of the World are poised to grow at a CAGR of more than 6% and 8% respectively by 2020. This region growth is attributed to aging population, rise in public awareness. Countries like China, India, Australia, and Brazil will be major contributors to the growth of the market.

Full Report With TOC @ http://www.researchmoz.us/global-radiopharmaceuticalsnuclear-medicine-market-analysis-trends-and-forecast-to-2020-report.html

Understanding the interlinked supply chain was a winning imperative for the market size estimation. Value chain analysis and pipeline analysis have contributed for consolidated market analysis, including the present and future impact of different factors. Demand and supply analysis identifies the potential risk of the interrupted supply of Mo-99 for the Tc-99m production, due to scheduled shutdown of major reactors and the benchmarking trend adopted by leading players to combat such operational difficulties.

Some of the key players contributing at a global level for nuclear medicine market growth are Cardinal Health, Inc. (United States), Cambridge Isotope Laboratories (United States), GE Healthcare (United Kingdom), IBA Group (Belgium) and Lantheus Medical Imaging, Inc. (United Sates).

This report provides in-depth market assessment across the major geographies such as:

North America
Europe
Asia-Pacific (APAC)
Rest of the World (RoW)

Reasons to Buy:

Nuclear medicine/Radiopharmaceuticals usage and demand by various end-users across the globe
Emerging isotopes as well as alternative isotopes for use both in the SPECT and PET segments
Emerging applications in Nuclear Medicine
Regulations and Reimbursement scenario
Stable isotopes study being a value addition
Competitive landscaping and Major player profiles

The nuclear medicine market by indication is segmented as oncology, cardiology, inflammation, nephrology, neurology, lymphology, thyroid glands, and gastro intestinal. Cardiology holds the largest share in 2013 in SPECT nuclear medicine market whereas nephrology is the fastest growing application of this segment. Increasing incidence of cardiac ailments, aging population, and preference for non invasive diagnostic procedures are driving the market for cardiology segment. Oncology contributes to the largest share of around $1 billion and is also the fastest growing segment in PET market with a CAGR of more than 7%. Nephrology is the fastest growing segment in the therapeutics. Increase in therapeutic application, public awareness, use of hybrid imaging, technological advancements, cyclotron production of radiopharmaceuticals, efficient diagnosis and treatments, emerging radioisotopes and replacement of traditional equipment are factors or opportunities expected to drive the nuclear medicine market. However, stringent regulatory issues, supply shortage, radio toxicity, high cost and huge investment are factors hindering the market growth during the forecasted period.

All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html

Every year nearly 30 million nuclear imaging procedures are performed using Technetium (Tc-99). Molybdenum (Mo-99) is the target material for Tc -99 with a half-life of 66 hours and is produced from Uranium (U-235) irradiation in nuclear reactors. The purified Mo-99 is sent to Technetium generators where Tc-99 is produced and sent to hospitals. The Technetium generator market is dominated by two companies Mallinckrodt Plc and Lantheus Medical Imaging Inc.

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis.We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports.We provide our services to all sizes of organizations and across all industry verticals and markets.Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030        
Email: sales(at)researchmoz(dot)us
http://www.researchmoz.us/

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Michelle Thoras
ResearchMoz
+1-518-618-1030
Email >
Follow us on
Visit website